<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117482">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573624</url>
  </required_header>
  <id_info>
    <org_study_id>115938</org_study_id>
    <nct_id>NCT01573624</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma</brief_title>
  <acronym>ILA115938</acronym>
  <official_title>A Multi-center, Randomized, Double-blind, Dose-ranging Study to Evaluate GSK573719 in Combination With Fluticasone Furoate, Fluticasone Furoate Alone, and an Active Control of Fluticasone Furoate/Vilanterol Combination in Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary: The purpose of this study is to characterize the dose response of GSK573719
      in combination with Fluticasone furoate 100mcg in patients with asthma. Treatment with
      inhaled Fluticasone furoate and Fluticasone furoate/Vilanterol are included as an active
      control.

      Detailed Description: Long acting muscarinic receptor antagonists (anti-cholinergic
      bronhcodilator) exert their effects via distinct and complementary bronchodilator mechanisms
      on large and small airways. Most of the experience with older anti-cholinergics had been
      with acute use and little is known about their effect in chronic use in asthma. This is a
      multicenter, randomized, double-blind, crossover study to evaluate 5 doses of inhaled
      GSK573719 inhaled over 14 days in patients with asthma. Fluticasone furoate (100 mcg) and
      Fluticasone furoate/Vilanterol (100/59mcg) will be included as an active comparator. Each
      eligible subject will receive a sequence of 3 of 7 potential treatments for a total of 3
      treatment periods per subject. The total duration of subject participation is approximately
      14 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Trough FEV1</measure>
    <time_frame>Day 14</time_frame>
    <description>FEV1 value obtained 24 hours after morning dosing on day 14 of each treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from baseline in Daily AM/PM Peak Expiratory Flow</measure>
    <time_frame>Day 7-14</time_frame>
    <description>Daily AM/PM (pre-dose and pre-rescue bronchodilator) PEF; calculated from the last 7 days of each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from baseline in Rescue albuterol use</measure>
    <time_frame>Day 7-14</time_frame>
    <description>Rescue albuterol/salbutamol use calculated from the 7 days prior to each treatment period as baseline and the last 7 days of each treatment period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">421</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone Furoate (FF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mcg, inhaled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Furoate /Vilanterol (VI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100/25mcg inhaled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Furoate/GSK573719</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100/15.6-250mcg inhaled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/GSK573719</intervention_name>
    <description>100/15.6</description>
    <arm_group_label>Fluticasone Furoate/GSK573719</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/GSK573719</intervention_name>
    <description>100/31.25</description>
    <arm_group_label>Fluticasone Furoate/GSK573719</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/GSK573719</intervention_name>
    <description>100/62.5</description>
    <arm_group_label>Fluticasone Furoate/GSK573719</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/GSK573719</intervention_name>
    <description>100/125</description>
    <arm_group_label>Fluticasone Furoate/GSK573719</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/GSK573719</intervention_name>
    <description>100/250</description>
    <arm_group_label>Fluticasone Furoate/GSK573719</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF</intervention_name>
    <description>100</description>
    <arm_group_label>Fluticasone Furoate (FF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/VI</intervention_name>
    <description>100/25</description>
    <arm_group_label>Fluticasone Furoate /Vilanterol (VI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient

          -  18 years of age or older at Visit 1

          -  Diagnosis of Asthma

          -  Male or eligible Female

          -  Pre-bronchodilator FEV1 of 40-80% of the predicted normal value at Visit 1

          -  Demonstrated reversibility by ≥12% and ≥200mL of FEV1 within 40 minutes following
             albuterol at Visit 1

          -  A need for regular controller therapy (i.e., inhaled corticosteroids alone or in
             combination with a long‐acting beta‐agonist, or leukotriene modifier etc.,) for a
             minimum of 8 weeks prior to Visit 1.

        Exclusion Criteria:

          -  History of Life threatening asthma

          -  Respiratory infection not resolved

          -  Asthma exacerbation

          -  Concurrent respiratory disease

          -  Current Smokers

          -  Other diseases that are uncontrolled disease or disease state that, in the opinion of
             the investigator, would put the safety of the patient at risk through study
             participation or would confound the interpretation of the efficacy results if the
             condition/disease exacerbated during the study

          -  A positive Hepatitis B surface antigen or positive Hepatitis C antibody and/or HIV

          -  Visual clinical evidence of oropharyngeal candidiasis

          -  Drug or milk protein allergies

          -  Concomitant medications affecting course of asthma

          -  Use of any other investigational medication within 30 days or 5 drug half-lives
             (whichever is longer)

          -  Previous use of GSK573719

          -  Any disease preventing use of anticholinergics

          -  Any condition that impairs compliance with study protocol including visit schedule
             and completion of daily diaries

          -  Any subject with a history of alcohol or substance abuse

          -  Any affiliation with Investigator's site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1424BSF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucumán</city>
        <zip>T4000DGF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puente Alto - Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7500551</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7500800</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>8880465</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Talca</city>
        <state>Región Metro De Santiago</state>
        <zip>3460001</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Valparaíso</state>
        <zip>2341131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Klin</city>
        <zip>141600</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115 280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>123367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ufa</city>
        <zip>450071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 14, 2014</lastchanged_date>
  <firstreceived_date>April 5, 2012</firstreceived_date>
  <firstreceived_results_disposition_date>July 25, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vilanterol (VI),</keyword>
  <keyword>, Fluticasone Furoate (FF),</keyword>
  <keyword>Adults</keyword>
  <keyword>Asthma</keyword>
  <keyword>GSK573719,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
